- CEPI will harness IQVIA’s expertise and resources in
implementing global clinical research strategies and procedures to
rapidly initiate clinical evidence generation around vaccines and
other biological countermeasures in response to future health
emergencies.
- Collaboration will also support a multi-regional research
preparedness initiative to strengthen clinical research capacity in
Low- and Middle-Income Countries, with an aim to get high quality
clinical trials up and running as quickly as possible once an
outbreak has been identified.
- CEPI/ IQVIA collaboration will contribute to the 100 Days
Mission, spearheaded by CEPI and embraced by the G7 and G20, for
faster, more equitable responses to future outbreaks and
pandemics
IQVIA, (NYSE:IQV), a leading global provider of advanced
analytics, technology solutions, and clinical research services,
and The Coalition for Epidemic Preparedness Innovations (CEPI)
today announced a strategic collaboration to advance the 100 Days
Mission.
In conjunction with national and regional collaborators, CEPI
and IQVIA will aim to enhance the world’s preparedness to rapidly
conduct life-saving clinical research for vaccines and other
biological countermeasures against emerging infectious diseases.
CEPI will harness IQVIA’s extensive clinical research expertise and
innovative solutions, as well as its global reach, to support its
goal of strengthening pandemic preparedness clinical research
capability in Low- and Middle-Income Countries (LMICs) to
accelerate vaccine development when faced with future viral
threats.
High-quality, sustainable clinical research capacity in
outbreak-prone areas, utilizing standardized processes, protocols
and data management systems, could significantly increase the speed
at which data about outbreaks and new vaccines can be generated
during future outbreaks of infectious disease. This clinical
research preparedness has been identified as a key enabler of the
100 Days Mission: a goal spearheaded by CEPI, and backed by the G7
and G20, which aims to accelerate the time taken to develop safe,
effective, globally accessible vaccines against emerging disease
outbreaks to within 100 days. The new collaboration between CEPI
and IQVIA will provide tools and resources to help enhance research
preparedness in underserved regions of LMICs during ‘peace time’
and support trial sites to respond quickly and effectively during
outbreaks.
“Underpinning the 100 Days Mission is the need to get high
quality clinical trials up and running as efficiently and swiftly
as possible once an outbreak has been identified – wherever in the
world that outbreak may be,” said Dr Richard Hatchett, CEO of CEPI.
“Preparedness is key to this approach: building sustainable
clinical research capacity during ‘peace time’ will enable trial
sites to respond and operate at pace when faced with an infectious
disease emergency. IQVIA’s world-class clinical research
experience, its cutting-edge tools and technologies, and its
footprint in LMICs makes it the ideal partner for our ambition to
strengthen regionally-led clinical research preparedness,
contributing to faster, more equitable responses to future
outbreaks and pandemics.”
“Recent pandemics have highlighted the lifesaving effect that
fast development, testing and manufacturing of effective vaccines
can have on the global community. IQVIA’s collaboration with CEPI
will support the 100 Days Mission in delivering transformative
healthcare worldwide. IQVIA is committed to Global Public Health
and through our extensive clinical networks, data, technology and
public health capabilities, we are able to accelerate healthcare
innovation for patients globally,” said Alistair Grenfell,
President, Europe, Middle East, Africa and South Asia, IQVIA.
As part of its mission to enable faster and more equitable
responses to future viral threats, CEPI will support the
establishment of regional consortia, comprised of and led by
national and regional stakeholders, to bolster research
preparedness across LMICs. The regional consortia will identify
gaps and needs in regional clinical research capability, and
oversee the building of sustainable research capacity that can be
swiftly put into action to respond to infectious disease
outbreaks.
IQVIA will play a crucial role as a global service provider,
utilizing its global reach and bandwidth to support the regional
consortia and CEPI to fill gaps that will accelerate the generation
of high-quality data during an outbreak response. Through this
strategic collaboration IQVIA will develop and provide innovative
tools and technologies to help facilitate more efficient and
standardized studies, particularly in low resource settings; and
provide quality management oversight and harmonization to ensure
that the highest quality standards are maintained across multiple
trial sites and regions. In the event of an outbreak, IQVIA will
provide surge capacity to support clinical trial sites, whenever
and wherever it may be needed across the globe.
About CEPI
CEPI is an innovative partnership between public, private,
philanthropic, and civil organizations, launched in 2017, to
develop vaccines against future epidemics. Its mission is to
accelerate the development of vaccines and other biologic
countermeasures against epidemic and pandemic threats so they can
be accessible to all people in need.
Prior to COVID-19, CEPI’s work focused on developing vaccines
against Ebola virus, Lassa virus, Middle East Respiratory Syndrome
coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya
virus – it has over 20 vaccine candidates against these pathogens
in development. CEPI has also invested in new platform technologies
for rapid vaccine development against unknown pathogens (Disease
X).
CEPI has played a central role in the global response to
COVID-19, supporting the development of the world’s largest
portfolio of vaccines against SARS-CoV-2 and its variants with a
focus on speed, scale and access, as well as co-leading COVAX, the
global initiative to deliver fair and equitable access to COVID-19
vaccines. CEPI is also the world’s leading funder of R&D for
broadly protective coronavirus vaccines which could protect against
future variants of COVID-19 as well as other coronaviruses with
epidemic and pandemic potential.
CEPI has embarked upon an ambitious US$3.5bn five-year plan –
called CEPI 2.0 – to dramatically reduce or even eliminate the
future risk of pandemics and epidemics. Central to the plan is
CEPI’s goal – supported by the G7 and G20 – to compress the time
taken to develop safe, effective, globally accessible vaccines
against new threats to just 100 days. Achieving this ‘100 Days
Mission’ would give the world a fighting chance of containing a
future outbreak before it spreads to become a global pandemic. Read
the plan at endpandemics.cepi.net.
To read more about how the world can work together to
#endpandemics, check out DISEASE X – The 100 Days Mission to End
Pandemics, by CEPI’s Chief Scientific Writer Kate Kelland,
available here at Bookshop.org. All author proceeds go to the World
Health Organization Foundation’s COVID-19 Response.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 87,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231011382538/en/
Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com)
+1.973.316.3828
Trent Brown, IQVIA Media Relations (trent.brown@iqvia.com)
+1.919.780.3221
CEPI Media Contact CEPI press@cepi.net +44 7387
055214
IQVIA (NYSE:IQV)
過去 株価チャート
から 8 2024 まで 9 2024
IQVIA (NYSE:IQV)
過去 株価チャート
から 9 2023 まで 9 2024